Baron, Frédéric http://orcid.org/0000-0002-2944-3812
Stevens-Kroef, Marian
Kicinski, Michal
Meloni, Giovanna
Muus, Petra
Marie, Jean-Pierre
Halkes, Constantijn J. M.
Thomas, Xavier
Vrhovac, Radovan
Specchia, Giorgina
Lefrere, Francois Sr
Sica, Simona
Mancini, Marco
Venditti, Adriano
Hagemeijer, Anne
Becker, Heiko
Jansen, Joop H.
Amadori, Sergio
de Witte, Theo
Willemze, Roelof
Suciu, Stefan
Funding for this research was provided by:
Fondation contre le cancer (This publication was supported by a donation from the "Fondation contre le cancer" from "Belgium" through the EORTC Cancer Research Fund.)
Article History
Received: 26 March 2018
Accepted: 13 June 2018
First Online: 20 June 2018
Compliance with ethical standards
:
: The current retrospective analysis includes only data from patients included in phase III multicenter prospective trials (either the EORTC/GIMEMA AML-10 or the EORTC/GIMEMA AML-12). Both prospective phase III trials were approved by the internal review boards of EORTC and GIMEMA and the ethical committee of each participating institution, and were conducted in accordance with the Declaration of Helsinki. All patients signed the respective informed consent form.
: Not applicable.
: Petra Muus has consulting or advisory role for Alexion, Opsona, Akari, and Ra Pharma and has a speaker’s bureau at Alexion. Xavier Thomas has consulting or advisory role for Celgene, Pfizer, Amgen, and Sunesis. Adriano Venditti has consulting or advisory role for Sandoz, Novartis, Janssen, and Jazz Pharmaceuticals and has received research grant from Sandoz. Heiko Becker has received honoraria from Bristol-Myers Squibb. Sergio Amadori has consulting or advisory role for Novartis, Celgene, and Abbvie. The other authors have nothing to disclose with respect to this manuscript.